Driving research of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS),
Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia and Long Covid

ME/CFS Collaborative
Research Center

at the CHU Sainte-Justine/
Université de Montréal

Clinical and scientific studies to understand and discover new treatments for Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME/CFS)

About the research center

The ME / CFS Collaborative Research Center, established in 2020 at CHU Sainte-Justine /Université de Montréal, increases OMF’s international collaborative efforts through the End ME/CFS Project. Directed by Alain Moreau, PhD, the Quebec, Canada-based laboratory has been researching ME / CFS for several years.

Alain Moreau, PhD, is a Full Professor in the Department of Stomatology, Faculty of Dentistry and Department of Biochemistry and Molecular Medicine, Faculty of Medicine, at Université de Montréal, Montréal, Québec, Canada. Additionally, Dr. Moreau is the Director of Network for Canadian Oral Health Research. He is the Scientific Director of the Viscogliosi Laboratory in Molecular Genetics of Musculoskeletal Diseases, Sainte-Justine University Research Center, Montréal, Québec.

Dr. Moreau’s chief interests of study are pediatric scoliosis, osteoarthritis, osteoporosis, and Myalgic Encephalomyelitis. Dr. Moreau is a member of the Open Medicine Foundation Scientific Advisory Board and is the Director of the Interdisciplinary Canadian Collaborative Myalgic Encephalomyelitis Research Network, a national research network funded by the Canadian Institute of Health Research.

Core Aims

Examine

the pathophysiology of ME/CFS, especially on severely affected persons

Address

the clinical heterogeneity of ME/CFS using provocation studies (stress-test)

Develop

a molecular diagnostic test

Integrate

a multi-omic approach to better stratify patients

Investigate

molecular profiling of discordant and concordant twins with ME/CFS

Study

multigenerational families affected by ME/CFS

Explore

possible treatment plans

Fundamental Philosophy

  • Establish collaborative work with ME / CFS groups to bring different fields of study together
  • Explore novel approaches to test for ME / CFS and treat the disease
  • Develop techniques to stratify ME / CFS patients
  • Predict which treatments will be most successful based on patient’s respective molecular profiling and symptoms
Ms-Evguenia-Nepotchatykh-and-Prof-Alain-Moreau-2.jpg

View our latest news

studies

Stress-Activated MicroRNAs

Studying microRNAs could help to bridge the conceptual gap between genetic predisposition and environmental factors causing ME/CFS or exacerbating specific symptoms.

Read More

Scientific Team

CHU Sainte-Justine Research Center
Université de Montréal

Alain Moreau, PhD , Scientific Director

Anita Franco, MSc, Lab coordinator

Dashen Wang, MD, PhD, Research Associate

Mohamed Elbakry, PhD , Research Associate

Viorica Lascau, MSc , Research coordinator – certification manager

Sophie Perreault, RN  , Clinical research nurse

Valerie Tremblay, RN, Clinical research nurse

Hélène Gagnon, RN, Clinical research nurse

Iurie Caraus, PhD , Postdoctoral fellow

Wesam Elremaly, PhD, Postdoctoral fellow

Lynda Chalder, MSc, PhD student

Evguenia Nepotchatykh, BSc, PhD student

Atefeh Moezzi, MSc, PhD student

Corinne Leveau, BSc, MSc student

Bita Rostami, BSc, MSc student

Marie-Yvonne Akoume PhD, Invited professor – ICanCME Research Network Investigator

Valérie Marcil PhD, Associate Professor – ICanCME Research Network Investigator

Emile Levy, MD, PhD ,Full Professor – ICanCME Research Network Investigator

University of Florida Atlantic

Dawei Li, PhD, Associated Professor – ICanCME Research Network Investigator

Jason Kost BSc , Research Assistant – ICanCME Research Network Member

SUPPORT OMF Funded Critical Research

Please help us expand our research efforts across the globe. Every donation brings us closer to a fully-funded research effort and the answers we all seek.

Learn about Our Other OMF Funded Collaborative Research Centers

Stay Informed

Be the first to hear our research news.

Subscribe Now.

No thanks

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation®

 

Averting a second pandemic:

Open Medicine Foundation leads groundbreaking international study of

Long COVID’s conversion to ME/CFS

AGOURA HILLS, CALIF.  — Open Medicine Foundation (OMF) is leading a large-scale international collaborative study investigating the potential conversion of Post-Acute Sequelae SARS-CoV-2 infection — more commonly known as Long COVID or Post-COVID Syndrome —  to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a chronic, life-altering disease with no known cause, diagnostic test or FDA approved treatments available.

Up to 2.5 million people in the U.S. alone suffer from ME/CFS; the COVID-19 pandemic could at least double that number. An estimated 35 percent of Americans who had COVID-19 have failed to fully recover several months after infection, prompting many to call it “a potential second pandemic.”

OMF recognized a familiar health crisis emerging, one with eerie similarities to ME/CFS. This crisis presented a unique opportunity to understand how a viral infection — in this case COVID-19 — may develop into ME/CFS in some patients. The goal is to find targeted treatments for ME/CFS patients and ultimately prevent its onset in people infected with SARS-CoV-2 or other infections.

The federal government is only now investing in Post-COVID research, with no focus on its connection to ME/CFS. OMF has already engaged researchers for the largest-scale study of its kind, solely supported by private donors who have contributed over one million dollars to date. When fully funded, the five million dollar, three-year study will be conducted across the globe at OMF funded Collaborative Research Centers, led by some of the world’s top researchers and ME/CFS experts.

BACKGROUND

In a significant percentage of patients, infections preceded their development of ME/CFS.  For example, according to the CDC about one in ten infected with Epstein-Barr virus, Ross River virus, or Coxiella burnetti develop symptoms that meet the criteria for ME/CFS.

THE STUDY

The ability to follow the development of ME/CFS from a known viral infection is unprecedented to date and crucial to researchers’ understanding of the disease. The focus of this study is to find the biological differences between persons returning to good health after COVID-19 and persons who remained ill more than six months after infection and developed ME/CFS.  Understanding these alterations in key pathways can lead to groundbreaking discoveries including new biomarkers, drug targets, and prevention and treatment strategies.

###

About Open Medicine Foundation

Established in 2012, Open Medicine Foundation leads the largest, concerted worldwide nonprofit effort to diagnose, treat, and prevent ME/CFS and related chronic, complex diseases such as Post Treatment Lyme Disease Syndrome, Fibromyalgia, and Post COVID. OMF adds urgency to the search for answers by driving transformational philanthropy into global research. We have raised over $28 Million from private donors and facilitated and funded the establishment of five prestigious ME/CFS Collaborative Research Centers around the world. To learn more, visit www.omf.ngo.

CONTACT:

Heather Ah San

Development and Communications Manager

1-650-242-8669

heather@omf.ngo